Cancer Clinical Trial
Official title:
Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm
Symptom Management, Quality of Life and Satisfaction with Care for Advanced Stage Cancers is the first part of a two part study (The Lancaster Cancer Care Model (LCCM) - Non-Concurrent Control Study). The primary aim of the study is to compare the proportion of advanced cancer patients who have a hospitalization or emergency department visit in the last 6 months of life before and after implementation of a new care model that provides more comprehensive symptom management and supportive care, including earlier referral to palliative care. The secondary comparative aim is to assess measures of quality of life and satisfaction in both groups. This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase).
Symptom Management, Quality of Life and Satisfaction with Care for Advanced Stage Cancers is
the first part of a two part study (The Lancaster Cancer Care Model (LCCM) - Non-Concurrent
Control Study) that was submitted to the National Cancer Institute (NCI) for funding. A
decision on funding the full study should be forthcoming in the early part of 2015. The
primary aim of the study is to compare the proportion of advanced cancer patients who have a
hospitalization or emergency department visit in the last 6 months of life before and after
implementation of a new care model that provides more comprehensive symptom management and
supportive care, including earlier referral to palliative care. The secondary comparative
aim is to assess measures of quality of life and satisfaction in both groups. To accomplish
the aims of the study by the end of the funding period, we propose to begin data collection
in advance of a funding decision. Should the study not receive funding, the data collected
will be used to inform decisions regarding other funding applications and/or implementation
of program changes at the Ann B. Barshinger Cancer Institute. Data collection does not
represent more than minimal risk for the patients enrolled.
This protocol is for the first phase of the study, which is the enrollment and collection of
data on the control group, to serve as the baseline for comparison regarding
hospitalizations, ED visits, quality of life, and patient and family satisfaction. To
achieve sufficient number of subjects and observed deaths in the control group, we are
targeting the start of enrollment and data collection in this group during the third quarter
of 2014. If the project is funded, the intervention and enrollment in the intervention group
are targeted to start in the second quarter of 2016. Background and study aims are presented
for the entire project to provide context, but the intent of this application is only for
approval of the enrollment and data collection on the control subjects (which contributes to
aims 2 and 3 of the larger project). A second protocol would be presented for review and
approval at the start of the intervention if the project funding is granted.
In phase one of the project, subjects would be approached and consented at the point of a
determination/diagnosis of advanced cancer and followed until the end of life or the start
of the intervention period in the 2nd quarter of 2016 (whichever comes first) per protocol.
This current study is to collect data on the control group only. After system redesign, we
will open an intervention arm study to collect data after implementation of the new care
model (about 18-24 months from start of control phase).
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|